The phase IV study for comparing the response of high-dose cytarabine therapy among the KIT mutation status in adult core binding factor acute myeloid leukemia. -JALSG CBF-AML209-KIT Study (CBF-AML209-KIT)
- Conditions
- Acute myeloid leukemia
- Registration Number
- JPRN-UMIN000003434
- Lead Sponsor
- Japan adult leukemia study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Not provided
(1)Secondary AML (2)The patients with the past history of hematopoietic disorder. (3)The patients who received the craniotomy. (4)The patients who received the total skull irradiation. (5)The patients who received the radiation therapy. (6)The patients who have been identified the cancer after the registration to the JALSG AML209-GS study. (7)The patients who have developed myocardial infarction or angina after the registration to the JALSG AML209-GS study. (8)The patients with cardiac dysfunction. (9)The patients with active gastric ulcer. (10)The patients with the uncontrollable ileus. (11)The patients with the diabetes mellitus. (12)The patients with active infection. (13)The patients in whom the HBV-reactivation have been observed. (14)Psycological patients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease-free survival at 2 years in CBF-AML patients with or without KIT mutation.
- Secondary Outcome Measures
Name Time Method